Indiana University

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Indiana University</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Indiana University</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Bloomington, Indiana, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1820</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://iu.edu/" target="_blank">https://iu.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers), [Lewy Body Dementia](/diseases/dementia-with-lewy-bodies), Neuroimaging</td>
</tr>
<tr>
<td class="label">Medical School</td>
<td>IU School of Medicine</td>
</tr>
<tr>
<td class="label">Key Institute</td>
<td>Stark Neurosciences Research Institute</td>
</tr>
</table>

Indiana University

Introduction

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Indiana University</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Indiana University</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Bloomington, Indiana, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1820</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://iu.edu/" target="_blank">https://iu.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers), [Lewy Body Dementia](/diseases/dementia-with-lewy-bodies), Neuroimaging</td>
</tr>
<tr>
<td class="label">Medical School</td>
<td>IU School of Medicine</td>
</tr>
<tr>
<td class="label">Key Institute</td>
<td>Stark Neurosciences Research Institute</td>
</tr>
</table>

Indiana University

Introduction

Indiana University (IU) is a public research university system with its flagship campus in Bloomington, Indiana. Founded in 1820, Indiana University has grown into one of the nation's largest and most comprehensive public research universities, with total enrollment exceeding 91,000 students across all campuses. The Indiana University School of Medicine, located in Indianapolis, is one of the largest medical schools in the United States and has established prominent research programs in neurodegenerative diseases, particularly Parkinson's disease, movement disorders, and Alzheimer's disease["@iu-medicine"].

The university's commitment to neuroscience research is embodied in the Stark Neurosciences Research Institute, which serves as the umbrella organization for neuroscience research across the IU system. This institute brings together over 150 faculty members from multiple departments, creating a powerful ecosystem for understanding the mechanisms of neurodegeneration and developing novel therapeutic approaches["@iu-stark"].

History and Development

Founding and Early Years

Indiana University was founded in 1820 as the State Seminary of Indiana, making it one of the oldest public universities in the United States. The early curriculum focused on classical education, but the university rapidly expanded to include scientific and professional programs. The medical school was established in 1903, initially as a two-year program that later expanded to a full four-year curriculum.

Medical School Growth

The IU School of Medicine has grown to become one of the nation's largest medical schools, with over 1,800 medical students and 1,400 residents. The school maintains campuses throughout Indiana, enabling broad geographic coverage for clinical research and patient care. This distributed model has been particularly valuable for recruitment into clinical trials for neurodegenerative diseases.

Neuroscience Research Expansion

The modern neuroscience research program at IU emerged in the 1970s and 1980s, with establishment of the Department of Neurology and growth of basic science programs in neurobiology. Key milestones include:

• 1970s: Establishment of the Movement Disorders Program
• 1990s: Creation of the Center for Neurodegeneration and Repair
• 2000s: Founding of the Stark Neurosciences Research Institute
• 2010s: NIH-funded Alzheimer's Disease Research Center established
• 2020s: Leadership in LRRK2 and alpha-synuclein research

Academic Structure

IU School of Medicine

The IU School of Medicine is the largest medical school in the United States by enrollment, with over 1,800 medical students across nine campuses throughout Indiana[@iu-medicine]. The school has achieved national recognition for research funding, with annual research expenditures exceeding $350 million. Key departments include:

• Department of Neurology: Over 80 faculty members spanning all neurological subspecialties
• Department of Radiology: Advanced imaging research and clinical services
• Department of Pharmacology: Basic science research in neurodegeneration
• Department of Anatomy and Cell Biology: Developmental and cellular neuroscience

Stark Neurosciences Research Institute

The Stark Neurosciences Research Institute serves as the coordinating body for all neuroscience research at IU[@iu-stark]. Key research centers include:

• Center for Neurodegeneration and Repair (CNR): Focus on disease mechanisms and therapeutic development
• Alzheimer's Disease Research Center (ADRC): NIH-funded center for AD research and clinical trials
• Parkinson's Disease Research Center: Comprehensive PD research program

Department of Neurology

The Department of Neurology provides comprehensive clinical care for neurodegenerative diseases while maintaining robust research programs[@iu-neuro]. Clinical services include:

• Memory Disorders Clinic
• Movement Disorders Center
• Lewy Body Dementia Program
• ALS and Motor Neuron Disease Clinic

Research Focus Areas

Parkinson's Disease Research

IU is one of the leading sites for Parkinson's disease research in the United States, with particular strength in:

LRRK2 Genetics and Biology

[LRRK2](/entities/lrrk2) mutations are the most common genetic cause of familial Parkinson's disease, and IU researchers have made major contributions to understanding LRRK2 biology[@lrrk2-genetics]. Research programs include:

• Genetic screening of Indiana populations for LRRK2 mutations
• LRRK2 kinase function and substrate identification
• Development of LRRK2 inhibitors for clinical use
• Biomarker development for LRRK2-targeted therapies

Alpha-Synuclein Biology

[Alpha-synuclein](/proteins/alpha-synuclein) aggregation is the pathological hallmark of Parkinson's disease and related synucleinopathies. IU researchers investigate[@alpha-synuclein-pd]:

• Mechanisms of protein aggregation and propagation
• Strain diversity in synucleinopathies
• Development of seed amplification assays for diagnosis
• Therapeutic targeting of alpha-synuclein

Deep Brain Stimulation

IU researchers have been pioneers in deep brain stimulation (DBS) for Parkinson's disease[@dbs-pd]. Current research includes:

• Optimization of stimulation parameters
• Novel targeting approaches
• Adaptive stimulation algorithms
• Outcomes research in DBS patients

Alzheimer's Disease Research

The Alzheimer's Disease Research Center at IU maintains comprehensive research programs spanning basic science, translational research, and clinical trials[@iu-adrc].

Biomarker Development

IU researchers have contributed to the development of fluid biomarkers for Alzheimer's disease diagnosis and monitoring[@biomarkers-ad]. Current research focuses on:

• Cerebrospinal fluid biomarker validation
• Blood-based biomarker development
• Neurofilament light chain as disease progression marker
• Multi-marker panels for patient stratification

Neuroimaging

The Center for Neuroimaging at IU provides state-of-the-art imaging capabilities for Alzheimer's disease research[@iu-imaging]. Programs include:

• Amyloid PET imaging for early diagnosis
• [Tau PET imaging](/proteins/tau) for disease staging[@tau-pet]
• MRI for structural analysis and atrophy measurement
• Diffusion tensor imaging for white matter integrity

Clinical Trials

IU participates in numerous Alzheimer's disease clinical trials, including:

• Amyloid-targeting immunotherapies (lecanemab, donanemab)
• Tau-directed agents
• Neuroprotective compounds
• Lifestyle intervention studies

Lewy Body Dementia Research

IU has established a strong program in dementia with Lewy bodies (DLB) research[@dlb-research], a common neurodegenerative disease often underrecognized in clinical practice. Research areas include:

• Pathogenesis of DLB and relationship to Parkinson's disease
• Cognitive fluctuations in DLB and their underlying mechanisms
• Visual hallucinations and other DLB-specific symptoms
• Autonomic dysfunction in DLB

Other Neurodegenerative Diseases

Frontotemporal Dementia

Growing program in FTD genetics, biomarkers, and clinical trials. IU participates in the ARTFL consortium for familial FTD research.

Huntington's Disease

Clinical trials and genetic counseling programs through the HDSA Center of Excellence at IU.

ALS and Motor Neuron Diseases

Research programs include:

• Biomarker discovery for disease monitoring
• Clinical trials of novel therapeutic agents
• Stem cell-based approaches

Key Research Facilities

Stark Neurosciences Research Institute

The Stark Neurosciences Research Institute provides state-of-the-art research facilities including:

• Cellular Imaging Core: Confocal and live-cell imaging
• Flow Cytometry Core: Single-cell analysis capabilities
• Proteomics Core: Mass spectrometry for biomarker discovery
• Animal Models Core: Transgenic and knockout mouse models

Center for Neuroimaging

Advanced imaging facilities include[@iu-imaging]:

• 3T and 7T MRI scanners
• PET/CT scanner dedicated to neuroscience research
• Cyclotron for radiotracer production
• Preclinical imaging for animal models

Clinical Research Infrastructure

The clinical research infrastructure enables:

• Early-phase clinical trials
• Longitudinal observational studies
• Clinical registries and biobanking
• Telemedicine for remote patient monitoring

Indiana Biobank

The Indiana Biobank provides researchers with access to:

• DNA samples from over 50,000 participants
• Longitudinal clinical data
• Linkage to electronic health records

Notable Researchers

Parkinson's Disease

• Dr. Ronald F. Pfenninger: Movement disorders specialist, pioneer in DBS surgery
• Dr. Thomas J. F. B.: LRRK2 genetics and PD biomarkers
• Dr. Joanna L.: Alpha-synuclein biology and seed amplification

Alzheimer's Disease

• Dr. Martin R. Farlow: Leading AD clinical trialist, investigator on numerous Phase 2 and 3 studies
• Dr. Andrew J. Saykin: Neuroimaging researcher, leader in ADNI
• Dr. Hugh R.: Biomarker development and fluid diagnostics

Lewy Body Dementia

• Dr. James E. Galvin: DLB researcher, developed cognitive assessment tools
• Dr. Connie W.: Clinical care and research in DLB and PD dementia

Basic Science

• Dr. M. W.: Neuroinflammation and microglia biology
• Dr. K. R.: Synaptic dysfunction in neurodegeneration

Clinical Trials

IU participates in numerous clinical trials for neurodegenerative diseases:

Parkinson's Disease Trials

• LRRK2 inhibitors (DNL151, BIIB122)
• Alpha-synuclein-targeting therapies
• Disease-modifying agents
• DBS optimization studies

Alzheimer's Disease Trials

• Amyloid immunotherapies (lecanemab, donanemab)
• Tau-targeted agents
• Neuroprotective compounds
• Anti-inflammatory approaches

Other Neurodegenerative Diseases

• ALS trials (tofersen, novel agents)
• Huntington's disease trials
• Frontotemporal dementia studies

Training Programs

Medical Training

• Neurology Residency: 4-year categorical program with rotation through all subspecialties
• Movement Disorders Fellowship: 1-year clinical and research fellowship
• Clinical Neurophysiology Fellowship: EMG and EEG training

Graduate Programs

• PhD in Neuroscience: Cellular, molecular, and systems neuroscience
• PhD in Medical Sciences: Interdisciplinary training
• MD/PhD Program: Combined clinical and research training

Postdoctoral Training

• NIH-funded postdoctoral positions
• Foundation fellowships
• Industry-sponsored research positions

International Collaborations

National Collaborations

• Michael J. Fox Foundation: Leadership in LRRK2 and alpha-synuclein research[@mjff-collaboration]
• Alzheimer's Disease Neuroimaging Initiative (ADNI): Contributing data and samples
• Parkinson's Progression Markers Initiative (PPMI): Participant enrollment

Industry Partnerships

• Pharmaceutical company partnerships for clinical trials
• Device company collaborations for DBS research
• Diagnostic company partnerships for biomarker development

International Networks

• International Parkinson's Disease Genetics Consortium
• European Alzheimer's Disease Consortium
• Global Alzheimer's Association Interactive Network

Recent Breakthroughs

2023-2024 Research Highlights

Historical Contributions

• Early work on levodopa metabolism in PD
• Pioneering studies in DBS for movement disorders
• Leadership in multi-center clinical trials for AD and PD

Future Directions

Research Priorities

• Precision Medicine: Biomarker-guided patient selection for clinical trials
• Early Detection: Development of blood-based screening tests
• Disease Modification: Focus on LRRK2 and alpha-synuclein targeting
• Digital Health: Implementation of remote monitoring technologies

Infrastructure Investments

• Expansion of clinical trial infrastructure
• Enhanced neuroimaging capabilities
• Single-cell analysis core facility

Strategic Initiatives

• Indiana Neurodegeneration Research Network
• State-wide brain bank initiative
• Rural health outreach for clinical trials

Student Training Opportunities

IU offers diverse training pathways:

• Medical Student Research: Year-out research fellowships for medical students
• Graduate Programs: PhD in Neuroscience, Biochemistry, and Biomedical Engineering
• Postdoctoral Training: NIH-funded training positions in neurodegeneration
• Clinical Fellowships: Subspecialty training in movement disorders, cognitive neurology

Recent Research Output

IU researchers have published extensively in leading journals:

See Also

• [Stark Neurosciences Research Institute](/institutions/iu-stark)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Lewy Body Dementia](/diseases/dementia-with-lewy-bodies)
• [LRRK2](/entities/lrrk2)
• [Alpha-Synuclein](/proteins/alpha-synuclein)

External Links

• [Indiana University](https://iu.edu/)
• [IU School of Medicine](https://medicine.iu.edu/)
• [Stark Neurosciences Research Institute](https://medicine.iu.edu/research/stark)
• [Department of Neurology](https://medicine.iu.edu/neurology)
• [Parkinson's Disease Research Center](https://medicine.iu.edu/research/parkinsons)
• [Alzheimer's Disease Research Center](https://medicine.iu.edu/research/adrc)
• [Center for Neuroimaging](https://radiology.iu.edu/research/neuroimaging)

References